Claris Lifesciences has gained 4% to Rs 170 on BSE after sterile injectables manufacturer on Tuesday after market hours said US health regulator has found its manufacturing facility acceptable after an inspection.
“The company has received a report from US Food and Drug Administration (FDA) for the inspection it conducted classifying the finished dosage plant and the active pharma ingredients (API) plant as acceptable," Claris Lifesciences said in a BSE filing.
The company has three manufacturing facilities at a campus located in Ahmedabad,Gujarat. The company manufactures and markets products across various therapeutic segments including anesthesia, blood products, anti-infective and renal care.
The stock opened at Rs 175 and touched a high of Rs 175 on BSE. The counter has seen huge trading activity with around 167,000 shares changing hands till 1110 hours, as against an average 135,000 shares that were traded daily in past two weeks on BSE.
“The company has received a report from US Food and Drug Administration (FDA) for the inspection it conducted classifying the finished dosage plant and the active pharma ingredients (API) plant as acceptable," Claris Lifesciences said in a BSE filing.
The company has three manufacturing facilities at a campus located in Ahmedabad,Gujarat. The company manufactures and markets products across various therapeutic segments including anesthesia, blood products, anti-infective and renal care.
The stock opened at Rs 175 and touched a high of Rs 175 on BSE. The counter has seen huge trading activity with around 167,000 shares changing hands till 1110 hours, as against an average 135,000 shares that were traded daily in past two weeks on BSE.
